ALK-Abelló A/S
ALK-B.CODrugs in Pipeline
39
Phase 3 Programs
28
Upcoming Catalysts
1
Next Catalyst
Sep 2026
Market Overview
Stock performance and key metrics
1 upcoming, 0 past
ALK HDM tablet
Asthma
ALK HDM AIT 6 DU
Asthma
Sublingual immunotherapy
Allergy
5-grass mix SLIT-drops
Allergy
MK-8237 tablets
Rhinitis, Allergic, Perennial
Grazax
Grass Pollen Allergy
Grazax-R
Allergy
SCH 39641 6 Amb a 1-U
Rhinitis; Allergic, With Asthma
AVANZ olea
Allergic Rhinitis Due to Olea Europaea Pollen
HDM SLIT-tablet (12 SQ-HDM)
Allergic Rhinoconjunctivitis
SLITone(TM) Dermatophagoides mix
Allergy
AVANZ MITE
Allergic Rhinitis Due to Dust Mite
ALK Grass tablet - use of compliance device
Allergy
Sublingual allergy immunotherapy tablet
Allergic Rhinitis Due to Dermatophagoides Farinae
AVANZ Phleum pratense
Allergic Rhinoconjunctivitis
Grass (Phleum pratense) pollen allergen extract
Rhinitis Allergic
AIT Tablet
House Dust Mite Allergy
Ambrosia artemisiifolia allergen extract (Amb a 1-U)
Rhinitis, Allergic
ALK Grass tablet
Allergy
Grazax + Aerius
Allergic Rhinoconjunctivitis
Loratadine 10 mg Rescue Treatment
Rhinoconjunctivitis
SCH 39641
Allergy
Allergy vaccination (Alutard SQ)
Allergy
subcutaneous immunotherapy
Atopic Dermatitis
Pangramin SLIT HDM mix.
Allergic Rhinitis
HDM SLIT-tablet
Allergic Rhinitis
Tree SLIT-tablet
Allergy
SCH 697243
Rhinoconjunctivitis
MK-8237 6 DU
Rhinitis, Allergic, Perennial
AVANZ Salsola
Allergic Rhinoconjunctivitis Due to Salsola Kali Pollen
AVANZ Cupressus
Allergic Rhinoconjunctivitis
AVANZ Phleum pratense 15,000 SQ+
Grass Pollen Induced Allergic Rhinoconjunctivitis
oral immunotherapy
Allergy
Osiris Phleum pratense
Rhino-conjunctivitis
SQ tree SLIT-tablet
Allergic Rhinoconjunctivitis
Peanut SLIT-tablet
Peanut Allergy
Specific allergen immunotherapy
Cat Allergy
SLITone ULTRA HDM immunotherapy
Allergic Rhinitis
ALK tree AIT 0.5 DU
Birch Pollen Allergy
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
ALK HDM tablet | Phase 3 | Asthma | - | - |
ALK HDM AIT 6 DU | Phase 3 | Asthma | - | - |
Sublingual immunotherapy | Phase 3 | Allergy | - | - |
5-grass mix SLIT-drops | Phase 3 | Allergy | - | - |
MK-8237 tablets | Phase 3 | Rhinitis, Allergic, Perennial | - | - |
Grazax | Phase 3 | Grass Pollen Allergy | - | - |
Grazax-R | Phase 3 | Allergy | - | - |
SCH 39641 6 Amb a 1-U | Phase 3 | Rhinitis; Allergic, With Asthma | - | - |
AVANZ olea | Phase 3 | Allergic Rhinitis Due to Olea Europaea Pollen | - | - |
HDM SLIT-tablet (12 SQ-HDM) | Phase 3 | Allergic Rhinoconjunctivitis | - | - |
SLITone(TM) Dermatophagoides mix | Phase 3 | Allergy | - | - |
AVANZ MITE | Phase 3 | Allergic Rhinitis Due to Dust Mite | - | - |
ALK Grass tablet - use of compliance device | Phase 3 | Allergy | - | - |
Sublingual allergy immunotherapy tablet | Phase 3 | Allergic Rhinitis Due to Dermatophagoides Farinae | - | - |
AVANZ Phleum pratense | Phase 3 | Allergic Rhinoconjunctivitis | - | - |
Grass (Phleum pratense) pollen allergen extract | Phase 3 | Rhinitis Allergic | - | - |
AIT Tablet | Phase 3 | House Dust Mite Allergy | - | - |
Ambrosia artemisiifolia allergen extract (Amb a 1-U) | Phase 3 | Rhinitis, Allergic | - | - |
ALK Grass tablet | Phase 3 | Allergy | - | - |
Grazax + Aerius | Phase 3 | Allergic Rhinoconjunctivitis | - | - |
Loratadine 10 mg Rescue Treatment | Phase 3 | Rhinoconjunctivitis | - | - |
SCH 39641 | Phase 3 | Allergy | - | - |
Allergy vaccination (Alutard SQ) | Phase 3 | Allergy | - | - |
subcutaneous immunotherapy | Phase 3 | Atopic Dermatitis | - | - |
Pangramin SLIT HDM mix. | Phase 3 | Allergic Rhinitis | - | - |
HDM SLIT-tablet | Phase 3 | Allergic Rhinitis | - | - |
Tree SLIT-tablet | Phase 3 | Allergy | - | - |
SCH 697243 | Phase 3 | Rhinoconjunctivitis | - | - |
MK-8237 6 DU | Phase 2 | Rhinitis, Allergic, Perennial | - | - |
AVANZ Salsola | Phase 2 | Allergic Rhinoconjunctivitis Due to Salsola Kali Pollen | - | - |
AVANZ Cupressus | Phase 2 | Allergic Rhinoconjunctivitis | - | - |
AVANZ Phleum pratense 15,000 SQ+ | Phase 2 | Grass Pollen Induced Allergic Rhinoconjunctivitis | - | - |
oral immunotherapy | Phase 2 | Allergy | - | - |
Osiris Phleum pratense | Phase 2 | Rhino-conjunctivitis | - | - |
SQ tree SLIT-tablet | Phase 2 | Allergic Rhinoconjunctivitis | - | - |
Peanut SLIT-tablet | Phase 2 | Peanut Allergy | - | - |
Specific allergen immunotherapy | Phase 2 | Cat Allergy | - | - |
SLITone ULTRA HDM immunotherapy | Phase 2 | Allergic Rhinitis | - | - |
ALK tree AIT 0.5 DU | Phase 2 | Birch Pollen Allergy | - | - |
Full breakdown — the signals behind the verdict
Frequently asked questions
What is in ALK-Abelló A/S's drug pipeline?→
CatalystAlert tracks 39 drug candidates in ALK-Abelló A/S's (ALK-B.CO) pipeline across Phase 3, Phase 2. Its lead program is ALK HDM tablet (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is ALK-Abelló A/S's next FDA catalyst?→
ALK-Abelló A/S's (ALK-B.CO) next tracked catalyst is a Phase 3 expected September 6, 2026. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track ALK-B.CO biotech catalysts?→
Add ALK-B.CO to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow ALK-Abelló A/S's live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.